drugset / Trial / NCT06260072

Magnesium and Riboflavin Treatment for Post-Concussion Headache

NCT06260072

Phase 2 Recruiting 108 enrolled University of Virginia
RandomizedParallel-groupTriple-blindTreatment

Summary

This clinical trial will try to determine if the supplements magnesium and riboflavin will reduce the pain and duration of headaches in persons diagnosed with a concussion. The participant will be randomized to either active magnesium and riboflavin capsules or placebo (inert) capsules. The capsules will be taken once a day for 14 days. The participant will also complete a short diary form for the 14 days and will have 3 follow up visits either by telephone or in person.

Timeline

Start
2020-02-10
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Magnesium Oxide Small molecule 400 mg
Comparator Riboflavin Other / unclassified 100 mg

Indications

No indication recorded.